-
Navitoclax is an orally active Bcl-2 inhibitor targeting to Bcl-xL, Bcl-2, Bcl-w, with anti-tumor activity in vitro and in vivo.
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Pulrodemstat is a potent, selective, reversible and orally active LSD1 inhibitor, with anticancer effects.
-
Ganetespib is a unique Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies.
-
CC-90011 is a potent, selective, reversible and orally active LSD1 inhibitor that induces AML and SCLC cells differentiation.
-
Trilaciclib is a CDK4/6 inhibitor with IC50s of 1 nM/4 nM for CDK4/6, respectively. Use for chemotherapy-induced myelosuppression in vivo.
-
MCP110 is an inhibitor of Ras/Raf-1 interaction in human cancer cells. The Ras family GTPases play a central role in the growth factor signaling.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
Categories
Diseases
Others
Archives
- March 2023 (1)
- November 2022 (1)
- July 2022 (2)
- October 2021 (1)
- June 2021 (1)
- May 2021 (1)
- August 2020 (1)
- April 2019 (1)